Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01172054 · ClinicalTrials.gov registry record · Phase 1
Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults
A Phase 1 study, sponsored by VaxInnate Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 292
- Enrollment target
NCT01172054 is a Phase 1 study that has completed, run by VaxInnate Corporation. The registered enrollment target is 292 participants.
The verdict
NCT01172054, a Phase 1 study, has completed, sponsored by VaxInnate Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 292 participants
- Enrollment target
Study Summary
This is a multicenter, escalating dose-ranging study to assess the safety, reactogenicity and immunogenicity of 3 different novel H1N1 influenza vaccine constructs delivered i.m. as a single dose vaccination on day 0.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VAX128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01172054
The ClinicalTrials.gov registry entry for NCT01172054 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VaxInnate Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01172054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01172054 about?
NCT01172054 is a clinical study titled "Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults". This is a multicenter, escalating dose-ranging study to assess the safety, reactogenicity and immunogenicity of 3 different novel H1N1 influenza vaccine constructs delivered i.m. as a single dose vaccination on day 0.
What is the current status of trial NCT01172054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 292 participants. The study started on 2010-07. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01172054?
The interventions under investigation include: Placebo (BIOLOGICAL), VAX128 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01172054?
This trial is sponsored by VaxInnate Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.